Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Migraine Headache

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    177 result(s) found for: Migraine Headache. Displaying page 3 of 9.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2007-002667-28 Sponsor Protocol Number: 0974-031 Start Date*: 2008-05-29
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Multiple Attacks Study to Compare the Efficacy and Safety of Oral MK-0974 With Placebo for the Acute Treatment of Migraine With or Wi...
    Medical condition: Migraine
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027599 Migraine LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) CZ (Completed) ES (Completed) AT (Completed) DK (Completed) FR (Completed) NL (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003736-38 Sponsor Protocol Number: BIA-2093-209 Start Date*: 2009-02-17
    Sponsor Name:BIAL-Portela & Ca, S.A.
    Full Title: Efficacy and safety of Eslicarbazepine acetate as preventive therapy for patients with migraine: a double-blind, randomised, placebo-controlled, parallel-group, multicentre clinical trial
    Medical condition: Adult patients with migraine with or without aura
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027599 Migraine LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) DE (Completed) AT (Completed) ES (Completed) PT (Completed) SK (Completed) CZ (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004497-25 Sponsor Protocol Number: 18898A Start Date*: 2020-10-27
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, randomized, double-blind, parallel-group, placebo-controlled study with an extension period to evaluate the efficacy and safety of eptinezumab for the prevention of migraine in pati...
    Medical condition: Migraine in patients with unsuccessful prior preventive treatments
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) DK (Completed) FI (Completed) BE (Completed) PL (Completed) GB (GB - no longer in EU/EEA) SK (Completed) HU (Completed) SE (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000923-15 Sponsor Protocol Number: 20160172 Start Date*: 2018-06-14
    Sponsor Name:Amgen
    Full Title: A Phase I, Randomized, Open-label, Multiple-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of AMG 334 in Children and Adolescents With Migraine
    Medical condition: Migraine prevention
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2015-001883-21 Sponsor Protocol Number: I5Q-MC-CGAI Start Date*: 2016-01-18
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients with Chronic Migraine - the REGAIN Study
    Medical condition: Chronic Migraine Headache
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10027602 Migraine headache LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003761-18 Sponsor Protocol Number: BHV3000-312 Start Date*: 2022-01-20
    Sponsor Name:Biohaven Pharmaceuticals Inc.
    Full Title: Phase 3, multicenter, open-label study to assess the long-term safety and tolerability of rimegepant for the acute treatment of migraine (with or without aura) in children and adolescents ≥ 6 to < ...
    Medical condition: Acute Migraine (with or without aura)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027603 Migraine headaches HLT
    20.0 10029205 - Nervous system disorders 10052787 Migraine without aura PT
    20.0 10029205 - Nervous system disorders 10027607 Migraine with aura PT
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    21.1 10029205 - Nervous system disorders 10066635 Acute migraine LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003049-40 Sponsor Protocol Number: 20007A Start Date*: 2022-07-22
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, randomized, double-blind, parallel-group, placebo-controlled study of add-on eptinezumab treatment to brief educational intervention for the preventive treatment of migraine in pati...
    Medical condition: Migraine and medication overuse headache
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    20.0 10029205 - Nervous system disorders 10072720 Medication overuse headache PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) SE (Trial now transitioned) NO (Trial now transitioned) DE (Trial now transitioned) DK (Trial now transitioned) NL (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-001604-23 Sponsor Protocol Number: CLOP01 Start Date*: 2008-12-03
    Sponsor Name:Guy's & St Thomas' NHS Foundation Trust
    Full Title: A double blind placebo controlled trial investigating the efficacy of Clopidogrel as prophylactic treatment for migrane.
    Medical condition: Migraine
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027599 Migraine LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-004509-30 Sponsor Protocol Number: 012020 Start Date*: 2021-05-13
    Sponsor Name:INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON
    Full Title: A prospective structural, diffusion and connectomics MRI study on migraine patients treated with Fremanezumab
    Medical condition: MIGRAINE
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10027603 Migraine headaches HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000805-42 Sponsor Protocol Number: MeIn/06/Fro-pp/001 Start Date*: 2007-06-12
    Sponsor Name:Menarini International Operations Luxembourg S.A., Avenue de la Gare, 1611 Luxembourg, Luxembourg
    Full Title: A double-blind, cross-over patient preference study of frovatriptan versus zolmitriptan for the acute treatment of migraine
    Medical condition: Migraine with or without aura according to the IHS criteria
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027599 Migraine LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed) DK (Completed) ES (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002348-28 Sponsor Protocol Number: 0462-083 Start Date*: 2011-06-30
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, and Single-Dose Pharmacokinetics of MK-0462 in Migraineurs Aged 6 to 17 Years
    Medical condition: Migraine
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-003386-18 Sponsor Protocol Number: CandMigIII Start Date*: 2019-12-18
    Sponsor Name:Department of Neurology and Clinical Neurophysiology, St Olavs Hospital, Trondheim University hospital
    Full Title: CandMig III study Candesartan for migraine prevention: A multicentre, binational, triple blind, placebo controlled, parallel group study of two doses of candesartan (8 and 16 mg)
    Medical condition: Episodic migraine with and without aura
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10027603 Migraine headaches HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Completed) EE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005107-34 Sponsor Protocol Number: 07161 Start Date*: 2009-05-28
    Sponsor Name:University of Nottingham
    Full Title: A double blind parallel group randomised placebo controlled trial of Propranolol and Pizotifen in preventing migraine in children.
    Medical condition: Children and young people aged 5 years-16 years with Migraine with Out aura (MO), Migraine with Aura (MA), or Probable Migraine (PM) as defined by the International Headache Society (IHS) with 2 to...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027599 Migraine LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000600-42 Sponsor Protocol Number: I5Q-MC-CGAW Start Date*: 2018-06-26
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults with Treatment-Resistant Migraine - The CONQUER Study
    Medical condition: Treatment-resistant Migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10027602 Migraine headache LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) ES (Completed) CZ (Completed) BE (Completed) NL (Completed) HU (Completed) DK (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-004257-14 Sponsor Protocol Number: 0974-011 Start Date*: 2007-02-21
    Sponsor Name:Merck Sharp & Dohme (MSD)
    Full Title: A Multicenter, Double-Blind, Placebo and Active-Controlled, Parallel Group Study to Compare the Efficacy and Safety of Oral MK-0974 With Placebo and Zolmitriptan for the Acute Treatment of Migraine...
    Medical condition: Migraine
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027599 Migraine LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-002349-36 Sponsor Protocol Number: 0462-107 Start Date*: 2011-06-30
    Sponsor Name:Merck & Co., Inc.
    Full Title: An Open-Label Single-Dose Study to Evaluate the Pediatric Palatability of Maxalt Oral Disintegrating Tablets
    Medical condition: Migraine
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-004379-38 Sponsor Protocol Number: H8H-MC-LAHW Start Date*: Information not available in EudraCT
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients with Migraine
    Medical condition: Migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001306-41 Sponsor Protocol Number: ALD403-CLIN-011 Start Date*: 2017-04-27
    Sponsor Name:Alder BioPharmaceuticals, Inc.
    Full Title: A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients with Chronic Migraine
    Medical condition: Chronic Migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) DK (Completed) DE (Completed) BE (Completed) SK (Completed) HU (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-002086-31 Sponsor Protocol Number: RC 32\07 Start Date*: 2008-01-14
    Sponsor Name:ISTITUTO PER L'INFANZIA BURLO GAROFOLO
    Full Title: Randomized controlled Trial on the effectiveness of metoclopramide alone or in combination with ketoprofene, versus ketoprofene in acute migraine of child
    Medical condition: Acute Migraine in childhood
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027599 Migraine LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002201-22 Sponsor Protocol Number: CAMG334ADE03 Start Date*: 2019-08-28
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Assessment of Prolonged safety and tOLerability of erenumab in migraine patients in a Long-term OpeN-label study (APOLLON)
    Medical condition: Migraine prophylaxis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 13 08:10:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA